Updated May 12, 2026 · 785 articles
News
Latest market intelligence, industry updates, and institutional investing news from SEC filings data.
George Kurtz Sells $20M of CrowdStrike on Daily Cadence
CrowdStrike CEO George Kurtz's most recent Form 4 stack shows 2,500-share daily sales at $498-528 - the unmistakable cadence of a Rule 10b5-1 plan, executing into post-outage recovery prices.
Alex RiveraEU Targets Meta's Teen Algorithm: 13F Holder Concentration Map
Brussels' new Digital Fairness Act takes aim at TikTok and Meta's recommendation engines for minors. Meta's $113B BlackRock anchor and 5,297-holder long tail set up an unusual regulatory-risk transmission path.
Alex RiveraUnited Flight Attendants Win 31% Raise: 13F Holder Reaction Map
United Airlines flight attendants ratified a contract delivering 31% raises this summer. The cost lands on a holder base concentrated in margin-sensitive active managers — including five of the top six.
Alex RiveraGameStop's $56B eBay Bid: What the 13D Tape Reveals
GameStop's $125-per-share offer for eBay was filed as an SC 13D on May 4 but rejected within days. Institutional ownership data shows why the bid was always going to be a stretch.
Alex RiveraApple Chairman Levinson's $71M May Block: Cadence Read
Apple Chairman Arthur Levinson disposed of 250,000 AAPL shares on May 6, 2026 for cash proceeds of roughly $71.2 million. The single-day block runs 2.5 times the size of his prior quarterly cadence, and warrants closer reading than a routine plan tranche.
Alex RiveraMorningstar Founder Joe Mansueto: Decoding May Drip
Morningstar founder Joe Mansueto sold an identical 7,250-share block for five separate trading days in early May 2026. The cadence is a clean Rule 10b5-1 plan signature, and the disposition is small relative to his 37.5% beneficial-ownership disclosure.
Alex RiveraCrowdStrike CEO Kurtz: Reading the 10b5-1 Daily Drip
CrowdStrike CEO George Kurtz sold an identical 2,500-share block for four consecutive trading days in early May 2026 at prices ranging from $456 to $528. The cadence is the textbook signature of a Rule 10b5-1 plan, and it tells you more about plan design than it does about Kurtz's view of the stock.
Alex RiveraMusk's China Trip: A Read on Tesla's Cap Table
Elon Musk and Tim Cook are slated to join President Trump on a Beijing trip aimed at resetting US-China trade terms. Musk's 20.30% Tesla stake remains the largest single position on the cap table, freshly re-disclosed via SC 13G/A on April 23, 2026.
Alex RiveraGoogle's Googlebooks Bet: Reading the 13F Tape
Google has unveiled Googlebooks, a line of AI-native laptops built around Gemini. The institutional ownership tape behind Alphabet is one of the deepest on the market, and the most recent 13D/G filings reveal a still-relevant Brin stake plus the same Vanguard passive consolidation we are seeing on every mega-cap name.
Alex RiveraBristol-Myers' $15.2B Hengrui Deal: Holder Read
Bristol-Myers Squibb has signed a licensing agreement with Hengrui Pharma worth up to $15.2 billion across 13 assets. The 13F ownership data shows two deep-value houses already running outsized concentrated positions in BMY before the pact landed.
Alex RiveraGM Cuts 500-600 IT Jobs: What Value-Fund Holders See
General Motors is laying off 500 to 600 information technology employees as it shifts work toward AI tooling. The 13F holder base tells a more nuanced story: a handful of value-oriented active managers continue to run outsized weights in the stock, and Vanguard just filed a new 13G disclosing 7.47% ownership.
Alex RiveraJohn Hess Sells $36M CVX Post-Merger: Cadence Read
John Hess sold $36M of CVX across May 6-7, 2026 — his second large post-merger distribution after a similar $35M November 2025 window. Cadence is consistent with a programmed founder liquidity plan, not opportunistic timing.
Alex RiveraJoe Mansueto's MORN May Sale: 37.5% Founder Stake Intact
Morningstar founder Joseph Mansueto sold ~$900K of MORN on 2026-05-07 across 8 micro-lot prints. His 13G beneficial ownership remains 37.5% (14.9M shares), with brother Daniel at 9.5% — a 47% combined family stake.
Alex RiveraCharles Schwab Sells $19M SCHW: Plan-Driven Cadence Read
Charles Schwab, the 88-year-old founder, sold $19.1M of SCHW Class A across 5 sessions in late April-May 2026 — at meaningfully lower prices than February. Holds 110M+ shares total via Form 4 Table I and Table II.
Alex RiveraRVMD Pancreatic Data: Nextech's 58% Portfolio Bet Validated
Revolution Medicines' daraxonrasib data suggests doubled survival in pancreatic cancer. The 13F filings reveal a holder base built around exactly this thesis: Nextech Invest at 58.5% portfolio weight, Paradigm Biocapital at 13.5%, Alphabet at $320M.
Alex RiveraSAP Sapphire 2026 AI Suite: WindAcre's 6.39% Conviction Bet
SAP's Autonomous Enterprise AI launch at Sapphire 2026 lands on a holder base with one defining tell: WindAcre Partnership runs SAP at 6.39% of its entire portfolio, treating the AI thesis as a top-three position.
Alex RiveraAmazon 30-Minute Delivery: How AMZN Active Holders Are Positioned
Amazon's 30-minute delivery rollout lands on a holder base where 16 of the top 20 institutional positions are active conviction money — not index flow. Fidelity and Capital Research lead with portfolio weights above 3.8%.
Alex RiveraUTHR Counsel Paul Mahon Banks $14.4M Across Three Sessions
Paul Mahon, United Therapeutics' EVP and General Counsel, has run a biweekly exercise-and-sell cadence across three Form 4 filings — April 2, April 16, and May 7. Each session: 8,300 options exercised at a $146.03 strike, 8,300 common shares sold at $565-$597. Combined April-May proceeds: $14.4M.
Alex RiveraArista CTO Ken Duda's April 17: $9.5M Across 58K Shares
Ken Duda, Arista Networks' President and CTO and a co-founder, filed Form 4 on April 21, 2026 disclosing an April 17 exercise-and-sell cascade: 64,000 options exercised at a $15.2625 strike and 58,000 common shares sold at $161.18 to $164.86. Lifetime ANET sells now exceed $747.8M.
Alex RiveraSanofi Sits in Inhibrx's Top 5 as Phase 2 Lands: M&A Read
Inhibrx Biosciences reported midphase results for INBRX-106 paired with Keytruda. The headline is the data. The story behind the data is the holder file — Sanofi's strategic stake, Perceptive and Viking's biotech-specialist sizing, and what the 13G ownership thresholds say about who is positioned for a take-out.
Alex Rivera